International Journal of Biomedicine (Sep 2019)

Multicomponent Polysaccharide Essential Formula of Wound Healing Medicines Enriched with Fibroblast Growth Factor

  • Ekaterina V. Silina,
  • Nikolay V. Khokhlov,
  • Victor A. Stupin,
  • Natalya E. Manturova,
  • Vitaliy I. Vasin,
  • Evgeniy V. Velikanov,
  • Anton L. Popov,
  • Vadim B. Gavrilyuk,
  • Elena B. Artyushkova,
  • Mikhail P. Gladchenko,
  • Alexander V. Ivanov,
  • Victor T. Dudka,
  • Alexey A. Kryukov,
  • Yuri V. Furman,
  • Anton N. Kaplin,
  • Alexander V. Anikanov,
  • Marina A. Chernyatina,
  • Ekaterina V. Anurova

DOI
https://doi.org/10.21103/Article9(3)_OA12
Journal volume & issue
Vol. 9, no. 3
pp. 247 – 250

Abstract

Read online

The purpose of this research work was the creation of a safe and effective wound healing drug, in the multicomponent polysaccharide base of which the fibroblast growth factor is integrated in the optimal concentration. Materials and Methods: The present work was carried out in three stages. In Stage 1, the essential formula of a wound healing drug was created. In order to optimize the composition of the base formula, studies were conducted with various concentrations of structure-forming polysaccharides. In Stage 2, we performed technical tests of the gel composition of the medical product on hMSCs culture, and determined the optimal concentration of the growth factor, which was added to the base formula developed at Stage 1 in different concentrations. In Stage 3, an experimental safety study of the developed gel composition, including growth factors, was performed on laboratory animals. In an experimental safety study (subchronic toxicity) on a wound model, sexually mature male rats and Wistar females of the same age (8–9 months) were used. In all animals, 2 wounds of standard size were modeled on the back. Taking into account the weight and gender, rats were distributed evenly into two experimental groups. Group 1 included rats we treated with a polysaccharide gel based on polymers. This polysaccharide gel included rhFGF-b. Group 2 was used as control (without treatment). Results: The laboratory, histological and gravimetric studies of the internal organs and wounds of the animals in the experimental and control groups did not reveal any regular pathomorphological changes indicating the presence of the general toxicological properties of the studied products. This indicates the safety in vivo of the product being developed. Conclusion: The studies conducted in vitro and in vivo allow us to proceed with studies determining the effectiveness of the developed wound healing medical product on laboratory animals.

Keywords